Consumers Taking GLP-1s for Weight Loss, Current or Discontinued, Drive Lasting Changes in Retail, Per New Acosta Group Study

They reduce appetite and slow down digestion. Users decrease with weight loss syringes. However, the active ingredient increasingly allows people to access other foods as well. The effect could have an impact on food manufacturers.

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control

With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% and

Study captures sharp uptake in use of new weight loss and glucose-lowering medications

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.

Consumers Taking GLP-1s for Weight Loss, Current or Discontinued, Drive Lasting Changes in Retail, Per New Acosta Group Study

76% of those who discontinued GLP-1s are eating the same amount or less and many report retaining healthy habits

(title) - Sonoma Valley Sun

Ozempic Reshapes The Kinds of Food People Eat. Those taking GLP-1RAs were most likely to reduce the amount of processed foods, sugary drinks, refined grains… The post (title) first appeared on Sonoma Valley Sun.

GLP-1 Drugs Could Reshape Canada's Food Industry

Canada's new obesity guidelines signal a shift in food consumption, with GLP-1 drugs impacting how and what Canadians—especially youth—eat. The post GLP-1 Drugs Could Reshape Canada’s Food Industry appeared first on Retail Insider.